1. Home
  2. RPRX vs GFL Comparison

RPRX vs GFL Comparison

Compare RPRX & GFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • GFL
  • Stock Information
  • Founded
  • RPRX 1996
  • GFL 2007
  • Country
  • RPRX United States
  • GFL Canada
  • Employees
  • RPRX N/A
  • GFL N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • GFL
  • Sector
  • RPRX Health Care
  • GFL
  • Exchange
  • RPRX Nasdaq
  • GFL Nasdaq
  • Market Cap
  • RPRX 16.2B
  • GFL 17.5B
  • IPO Year
  • RPRX 2020
  • GFL 2020
  • Fundamental
  • Price
  • RPRX $39.45
  • GFL $45.50
  • Analyst Decision
  • RPRX Strong Buy
  • GFL Strong Buy
  • Analyst Count
  • RPRX 3
  • GFL 10
  • Target Price
  • RPRX $46.00
  • GFL $57.97
  • AVG Volume (30 Days)
  • RPRX 3.9M
  • GFL 1.4M
  • Earning Date
  • RPRX 11-05-2025
  • GFL 11-05-2025
  • Dividend Yield
  • RPRX 2.23%
  • GFL 0.13%
  • EPS Growth
  • RPRX N/A
  • GFL N/A
  • EPS
  • RPRX 1.75
  • GFL 6.65
  • Revenue
  • RPRX $2,349,844,000.00
  • GFL $5,904,199,182.00
  • Revenue This Year
  • RPRX $36.16
  • GFL N/A
  • Revenue Next Year
  • RPRX $2.04
  • GFL $6.56
  • P/E Ratio
  • RPRX $22.53
  • GFL $6.84
  • Revenue Growth
  • RPRX 3.70
  • GFL 27.49
  • 52 Week Low
  • RPRX $24.05
  • GFL $41.29
  • 52 Week High
  • RPRX $41.24
  • GFL $52.00
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 60.31
  • GFL 56.57
  • Support Level
  • RPRX $38.82
  • GFL $43.04
  • Resistance Level
  • RPRX $40.01
  • GFL $44.56
  • Average True Range (ATR)
  • RPRX 1.19
  • GFL 1.01
  • MACD
  • RPRX 0.05
  • GFL 0.22
  • Stochastic Oscillator
  • RPRX 66.81
  • GFL 100.00

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About GFL GFL Environmental Inc. Subordinate voting shares no par value

GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.

Share on Social Networks: